Enanta Pharmaceuticals Inc
$ 14.01
-0.36%
17 Apr - close price
- Market Cap 406,561,000 USD
- Current Price $ 14.01
- High / Low $ 14.32 / 13.96
- Stock P/E N/A
- Book Value 4.36
- EPS -3.21
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.60 %
- 52 Week High 17.15
- 52 Week Low 4.96
About
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$18.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-09 | 2025-12-01 | 2025-08-11 | 2025-05-12 | 2025-02-10 | 2024-11-25 | 2024-08-05 | 2024-05-06 | 2024-01-26 | 2023-11-20 | 2023-08-07 | 2023-05-08 |
| Reported EPS | -0.42 | -0.87 | -0.85 | -1.06 | -1.05 | -1.36 | -1.07 | -1.47 | -1.58 | -1.33 | -1.86 | -1.79 |
| Estimated EPS | -0.81 | -1.01 | -0.88 | -1.14 | -1.35 | -0.92 | -1.45 | -1.33 | -1.19 | -2.15 | -2.34 | -1.98 |
| Surprise | 0.39 | 0.14 | 0.03 | 0.08 | 0.3 | -0.44 | 0.38 | -0.14 | -0.39 | 0.82 | 0.48 | 0.19 |
| Surprise Percentage | 48.1481% | 13.8614% | 3.4091% | 7.0175% | 22.2222% | -47.8261% | 26.2069% | -10.5263% | -32.7731% | 38.1395% | 20.5128% | 9.596% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ENTA
2026-04-13 15:40:14
Enanta Pharmaceuticals has initiated a Phase 1 clinical trial for EDP-978, an oral, once-daily KIT inhibitor designed to treat urticaria and other mast cell-driven diseases. The study will assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, with topline data anticipated in Q4 2026. This move represents a significant step in addressing the unmet medical needs of patients suffering from chronically debilitating inflammatory skin conditions.
2026-04-13 11:09:47
Enanta Pharmaceuticals has started a Phase 1 clinical trial for EDP-978, an oral, once-daily KIT inhibitor developed to treat urticaria and other mast cell-driven diseases. The trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of EDP-978 in healthy volunteers, with topline data expected in Q4 2026. This move represents a significant step in the company's immunology program to address unmet medical needs for patients suffering from these debilitating inflammatory skin conditions.
2026-04-13 11:09:46
Enanta Pharmaceuticals has dosed its first participant in a Phase 1 clinical trial for EDP-978, an oral, once-daily KIT inhibitor aimed at treating urticaria and other mast cell-driven diseases. The study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of EDP-978 in healthy volunteers, with topline data expected in Q4 2026. This move represents the company's lead immunology program advancing into clinical development, addressing a significant unmet medical need for new efficacious oral treatments for chronic urticaria.
2026-04-13 07:09:00
Enanta Pharmaceuticals has initiated a Phase 1 clinical trial for EDP-978, an oral KIT inhibitor targeting chronic urticaria and other mast cell-driven diseases. The trial will enroll 98 healthy volunteers to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, with topline data expected in Q4 2026. This news follows a significant patent dispute with Pfizer concerning its COVID-19 antiviral medication, Paxlovid, for which oral arguments are scheduled for May 2026.
2026-04-07 10:40:05
Enanta Pharmaceuticals will present data on zelicapavir, an oral, once-daily N-protein inhibitor for Respiratory Syncytial Virus (RSV) treatment, at ESCMID Global 2026. The presentations will include Phase 2b study results showing improved symptom resolution and reduced hospitalization rates in high-risk adults, along with new data on zelicapavir’s strong barrier against antiviral resistance from a pediatric Phase 2 study. These findings highlight the drug's potential efficacy and durability in combating RSV.
2026-04-03 08:40:59
Enanta Pharmaceuticals (NASDAQ:ENTA) has received a "Moderate Buy" consensus rating from eight analysts, with an average 12-month price target of $20.29. Despite beating recent earnings and revenue estimates, the company remains unprofitable. Institutional investors own nearly 95% of the stock, which is currently trading around $13.14.
